MLTX Q1 2023 Earnings — MoonLake Immunotherapeutics Revenue & Financial Results | Market Cap Arena

MLTXMoonLake Immunotherapeutics

$1B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$13M

Net Income

-$9M

EPS (Diluted)

$-0.31

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$67M

Total Liabilities

$8M

Stockholders' Equity

$42M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$13M	-$16M	+18.9%
Net Income	-$9M	-$16M	+43.3%

Revenue Segments

License

$300M100%